The estimated Net Worth of Wayne Weisman is at least $3.64 Milion dollars as of 15 November 2021. Mr. Weisman owns over 4,129 units of Recro Pharma Inc stock worth over $180,825 and over the last 11 years he sold REPH stock worth over $2,997,806. In addition, he makes $458,338 as Independent Chairman of the Board at Recro Pharma Inc.
Wayne has made over 18 trades of the Recro Pharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 4,129 units of REPH stock worth $6,317 on 15 November 2021.
The largest trade he's ever made was selling 100,000 units of Recro Pharma Inc stock on 15 August 2016 worth over $637,000. On average, Wayne trades about 11,326 units every 55 days since 2014. As of 15 November 2021 he still owns at least 86,519 units of Recro Pharma Inc stock.
You can see the complete history of Mr. Weisman stock trades at the bottom of the page.
Wayne B. Weisman J.D. serves as Independent Chairman of the Board of the Company. Mr. Weisman has been a director of the corporate general partner of the common general partner of SCP Vitalife, which beneficially owns approximately 13.2% of our outstanding stock as of March 15, 2019. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife. He has also led the activities of SCP Private Equity Partners II, L.P., a venture capital fund of which he and Mr. Churchill are principals, in the life sciences area; these activities include investments in the United States and Israel. He has also led several other technology investments for SCP Private Equity Partners II, L.P. He has been a member of the investment committee of the Vitalife Life Sciences funds since their inception in 2002 and has worked closely with these funds since then. Mr. Weisman was a member of the board of directors of CIP Capital, L.P., a small business investment company licensed by the U.S. Small Business Administration since its inception in 1991 until 2017. From 1992 to 1994, Mr. Weisman was executive vice president and member of the board of a public drug delivery technology company. In addition, he also operated a management and financial advisory firm focusing on the reorganization and turnaround of troubled companies and began his career practicing reorganization law at a large Philadelphia law firm. Mr. Weisman possesses extensive experience in venture capital investing, particularly in the life sciences area. In addition to being our Chairman, Mr. Weisman serves on the board of directors of ReWalk Robotics Ltd. and on the board of directors for a number of private companies. He is the Vice Chairman of the board of trustees of Young Scholars Charter School,. He is also an advisory board member of the Philadelphia-Israel Chamber of Commerce and Mid-Atlantic Diamond Ventures, the venture forum of Temple University.
As the Independent Chairman of the Board of Recro Pharma Inc, the total compensation of Wayne Weisman at Recro Pharma Inc is $458,338. There are 3 executives at Recro Pharma Inc getting paid more, with Geraldine Henwood having the highest compensation of $4,622,980.
Wayne Weisman is 64, he's been the Independent Chairman of the Board of Recro Pharma Inc since 2008. There are 4 older and 5 younger executives at Recro Pharma Inc. The oldest executive at Recro Pharma Inc is Winston Churchill, 79, who is the Independent Director.
Wayne's mailing address filed with the SEC is C/O REWALK ROBOTICS LTD., 3 HATNUFA ST. P.O. BOX 161, YOKNEAM ILIT L3, , 20692203.
Over the last 11 years, insiders at Recro Pharma Inc have traded over $25,533,136 worth of Recro Pharma Inc stock and bought 3,055,820 units worth $22,429,197 . The most active insiders traders include Healthcare Master Fund Ltd ..., Investment Company, Inc. Awm a James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of $151,953. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth $1,004.
Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
Recro Pharma Inc executives and other stock owners filed with the SEC include: